Begin with the population
SELECT enrolled 17,604 adults aged 45 or older with established cardiovascular disease and overweight or obesity, without diabetes. It compared once-weekly semaglutide 2.4 mg with placebo. Mean follow-up was 39.8 months. Those criteria matter: the result cannot be read as a measured benefit for every person interested in weight loss.
What the main outcome counted
The primary outcome combined cardiovascular death, nonfatal heart attack and nonfatal stroke. It occurred in 569 of 8,803 participants receiving semaglutide and 701 of 8,801 receiving placebo: 6.5% versus 8.0%. The reported hazard ratio was 0.80, often described as a 20% relative reduction. The absolute difference in the reported proportions was 1.5 percentage points over follow-up, not 20 percentage points.
Why both numbers belong in the headline
Relative and absolute numbers answer different questions. A relative effect summarizes the contrast between groups; an absolute difference places that contrast against the event frequency in the study. Neither supplies your personal probability of an event. When comparing articles, keep the population, endpoint and observation period next to the percentage. A reduction in a combined endpoint is also not a claim that every component changed by the same amount.
How the regulatory indication differs from a general claim
In March 2024, FDA approved Wegovy injection to reduce cardiovascular death, heart attack and stroke in adults with cardiovascular disease and overweight or obesity, alongside reduced-calorie eating and increased activity. Trial participants also received usual cardiovascular care. The finding does not mean existing heart treatment can be stopped or that every product described as semaglutide has been shown equivalent.
Benefit still needs a tolerability discussion
In SELECT, adverse events caused permanent trial-drug discontinuation in 16.6% of the semaglutide group and 8.2% of placebo. That is a different endpoint from the cardiovascular benefit. A useful clinical discussion considers both, together with your medical history and current prescribing information. This article explains evidence; it does not tell you to start or stop medication.
Turn the evidence into questions for your care team
Ask whether your health history resembles the population studied, which product is being considered, and how follow-up will coordinate with your existing clinicians. Separately ask the provider to explain membership fees, prescription costs and coverage support. A compelling drug study does not tell you which service has better support, lower total costs or more suitable care. Use reviews for those commercial questions.
Put the questions to work
Compare our researched providers or build your provider checklist.
Explore relevant provider reviews
Use these reviews to compare the published services and terms. Inclusion is a research starting point, not a recommendation for treatment.
Continue your research
Sources & scope
Sources checked October 12, 2026. This guide explains published information and consumer research questions; it is not a clinical evaluation.
Prices and terms can change. Confirm your specific offer directly with the provider.